Your session is about to expire
← Back to Search
Dupilumab for Allergic Bronchopulmonary Aspergillosis
Study Summary
This trial will study the effects of the medication dupilumab on people with Allergic Bronchopulmonary Aspergillosis, specifically looking at the rate of exacerbations, lung function, health-related quality of life, and other measures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 4 trial • 40 Patients • NCT04203797Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a respiratory infection in the past 4 weeks before screening.You have been diagnosed with both allergic bronchopulmonary aspergillosis (ABPA) and asthma.You have been diagnosed or suspected to have a condition called eosinophilic granulomatosis with polyangiitis (EGPA).You have a serious long-term lung disease, except for asthma with allergic bronchopulmonary aspergillosis (ABPA).You had a bad flare-up of a breathing problem and needed strong medicine to help you breathe better within the last 4 weeks.You have had a serious breathing problem that needed strong medicine or a hospital stay in the past year.Your lung function is very poor, with less than 30% of the normal expected capacity after using a medication to open up the airways.You weigh less than 30 kilograms.You are currently smoking or using e-cigarettes, or you have quit within the last 6 months, or you have a history of smoking a lot.
- Group 1: dupilumab
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can more people join this research project?
"Yes, the information on clinicaltrials.gov suggests that this clinical trial is currently searching for patients. The clinical trial was first posted on 9/15/2020 and was last updated on 10/17/2022. The clinical trial is searching for 170 participants at 24 sites."
Are there a number of research facilities testing this in North America?
"To make participating as convenient as possible, this clinical trial has 24 sites throughout Ottawa, H4a3j1, Atherton, and other cities."
What is the precedence for dupilumab as a treatment?
"Dupilumab is the focus of 53 different clinical trials, 14 of which are in the final stage. The majority of research facilities are based in Louisville, however, there are 2662 total locations running trials for dupilumab."
Has the FDA greenlit dupilumab for general use?
"dupilumab's safety is estimated to be a 3. This comes from the fact that dupilumab is in Phase 3 trials, which implies that there is both evidence of efficacy and multiple rounds of supporting data."
How many people are volunteering to participate in this research?
"That is accurate. The information found on clinicaltrials.gov shows that this study is currently looking for 170 participants between 24 sites. The clinical trial was first posted on 9/15/2020 and was last edited on 10/17/2022."
Has this treatment method been tested before?
"Dupilumab has been researched since 2015, when the first study was sponsored by Sanofi. 880 patients were involved in the first study. After Phase 3 approval, 53 clinical trials began in455 cities and 43 countries."
How is dupilumab typically used to treat patients?
"Dermatitis, atopic is often treated effectively with dupilumab. Additionally, dupilumab has shown to be successful in managing other conditions such as failure with corticosteroid therapy, eosinophil, and asthma."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger